Protection from parainfluenza-3 virus and persistence of infectious bovine rhinotracheitis virus in sheep vaccinated with a modified live IBR-PI-3 vaccine.
Ewes (N = 7) and their lambs (N = 12) were vaccinated with a commercial modified live infectious bovine rhinotracheitis-parainfluenza type 3 virus vaccine. Both the vaccinated ewes and lambs and a group of unvaccinated ewes (N = 8) and their lambs (N = 13) were subsequently challenged with virulent parainfluenza type 3 virus. Although absolute immunity to infection and clinical response was not conferred, the clinical response was less severe in vaccinated lambs. Vaccinated animals also shed parainfluenza type 3 virus in nasal secretions for a shorter time than nonvaccinated animals. Some vaccinated lambs developed a persistent infectious bovine rhinotracheitis virus infection that was recrudesced by treatment with dexamethasone. It was concluded that vaccination was of benefit in reducing the severity of infection with parainfluenza type 3 virus. However, the inclusion of infectious bovine rhinotracheitis virus in a vaccine for sheep respiratory tract disease is highly questionable as it might increase the risk factor associated with vaccination. The consequences of the persistence of infectious bovine rhinotracheitis virus are now known.
Lehmkuhl
H D
HD
Cutlip
R C
RC
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D002417:Cattle; D007242:Herpesvirus 1, Bovine / Q000276:immunology*; D007241:Infectious Bovine Rhinotracheitis / Q000517:prevention & control*; D010224:Parainfluenza Virus 3, Human / Q000276:immunology*; D018184:Paramyxoviridae Infections / Q000517:prevention & control / Q000662:veterinary*; D018108:Respirovirus / Q000276:immunology*; D012756:Sheep; D012757:Sheep Diseases / Q000517:prevention & control*; D014765:Viral Vaccines / Q000276:immunology
D000914:Antibodies, Viral; D014765:Viral Vaccines